News & Updates

Show Multimedia Only
COVID-linked MIS-C outcomes reassuring at 6 months
COVID-linked MIS-C outcomes reassuring at 6 months
31 Jan 2025
Dupilumab-associated ocular surface disease less common in children, teens with AD
Dupilumab-associated ocular surface disease less common in children, teens with AD
18 Jan 2025